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Abstract
PURPOSE: The objectives were to determine the effects of caffeine ingestion
and mouth rinsing on cycling performance, and to assess whether the CYP1A2 gene
is related to the size of the performance effects. METHODS: Thirty-eight recreational
cyclists completed four simulated 3-kilometer time trials (TT). Subjects ingested
either 6mg/kgBW of caffeine or placebo one hour prior to each TT. Additionally, 25
ml of 1.14% caffeine, or placebo solution was mouth rinsed before each TT.
Treatments were: placebo ingestion+placebo rinse (Placebo), placebo
ingestion+caffeine rinse (Rinse), caffeine ingestion+caffeine rinse (Ingestion+Rinse),
caffeine ingestion+placebo rinse (Ingestion). Subjects were genotyped and classified
as AA homozygotes or C allele carriers for the rs762551 polymorphism in CYP1A2.
Magnitude based inferences were used to evaluate treatment differences. RESULTS:
Both Ingestion+Rinse (‘likely’) and Ingestion (‘possibly’) improved performance
compared to Placebo. Performance differences between Ingestion+Rinse and
Ingestion and between Rinse and Placebo were ‘likely trivial.’ C allele carriers
experienced greater gains (‘likely’) with Ingestion compared to AA homozygotes.
Additional analyses revealed that caffeine intake conferred larger benefits for
subjects that performed trials prior to 10am. CONCLUSIONS: Caffeine ingestion, but
not mouth rinse, improved cycling performance. C allele carriers experienced the
largest improvement in performance with caffeine ingestion, especially prior to
10am.

vi

Chapter One
Introduction
Consumption of caffeinated beverages began no later than 750-1000AD (19).
Caffeine was first isolated by Friedrich Ferdinand Runge in 1819 with the intention
of treating diseases associated with aging (39). Today, caffeine is the most
consumed psychoactive drug in the world, with an estimated worldwide daily intake
of ~75mg/person (18). Fredholm et al. reported that Scandinavian countries
consume >400mg caffeine/person/day, whereas countries such Nigeria and Angola
consume as little as 5mg caffeine/person/day (18). The widespread use of caffeine
in humans is primarily attributed to the stimulatory effect of caffeine on the central
nervous system, enhancing alertness. Caffeine has also proliferated into the world of
athletics and the last four decades have yielded sufficient scientific evidence for the
efficacy of caffeine ingestion on sprinting and endurance exercise performance (14).
In cyclists, caffeine can enhance 1km and 4km sprinting performance (42, 49).
Likewise, caffeine provision can improve short duration swimming performance (8),
rowing (5), running (20), and performance in variable intensity activities such as
tennis and team sports (29, 43). In 2004, a meta-analysis of 40 studies revealed that
caffeine intake markedly influences endurance performance, confirming the
effectiveness of caffeine use in events greater than 60 minutes (14).
The mechanism by which caffeine improves performance has drawn
considerable interest. Early thinking was that caffeine spared muscle glycogen and
enhanced fat oxidation during endurance exercise (11, 15, 27, 45) but this notion
has largely been discarded (21, 22, 23, 31). Caffeine is now believed to deliver its
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effects through the central nervous system (17). Adenosine decreases neuron firing
and the release of most neurotransmitters including acetylcholine, dopamine, and
noradrenaline (44). Caffeine is an adenosine antagonist that competitively binds to
adenosine receptors, thereby promoting continued neuron activity. Likely through
this mechanism, caffeine provision can suppress ratings of perceived exertion and
pain (11, 37), and increase neural excitability (47) thereby enhancing athletic
performance.
Though it is evident that caffeine ingestion can improve performance in
events of short and long durations, not all subjects experience the same benefits.
There is considerable individual variability with respect to caffeine responsiveness,
with some subjects exhibiting no effect at all (6). Genetics have consequently been
implicated as an explanation for the individualized ergogenic response to caffeine
ingestion (9). In an attempt to address whether or not genetics contribute to the
individual ergogenic effect of caffeine, our laboratory recently determined that
individuals homozygous for a single nucleotide (A) polymorphism at intron 1 of the
cytochrome P450 (CYP1A2) gene appeared to experience a larger ergogenic effect
following caffeine ingestion (50). Therefore, there may be a genetic predisposition
for responsiveness to caffeine ingestion that is greater in some people than in
others. Caffeine is metabolized in the liver by the cytochrome P450-1A2 enzyme,
which is coded for by the CYP1A2 gene (51). Being homozygous for the A allele
increases the inducibility of the P450-1A2 enzyme (41). If the expression of the
P450-1A2 enzyme is increased, as it is in individuals with the A/A genotype, then
the rate of caffeine metabolism may also increase. Quicker metabolism of caffeine in
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the liver may lead to a higher concentration of caffeine metabolites in the blood that
in turn would act on the central nervous system, consequently improving
performance.
Beaven and colleagues recently reported that without ingesting, but by
rinsing caffeine in the mouth, repeated sprinting performance is enhanced in
cyclists (1). It is logical to speculate that there are unidentified caffeine receptors in
the oral cavity that respond to the presence of caffeine by transmitting signals to the
areas of the brain involved in reward and motor activity, much like what has been
shown with carbohydrates (6). Interestingly, in the same study by Beaven, it was
also revealed that a caffeine-carbohydrate mouth rinse improved performance
beyond that of only a carbohydrate mouth rinse, providing more support for an oral
receptor in the mouth for caffeine (1). More research is necessary to profile the
efficacy of a caffeine mouth rinse on performance, particularly in real-world time
trial scenarios. The idea that mouth rinsing with caffeine can enhance performance
through a mechanism not influenced by liver caffeine metabolism invites the
possibility that genetic non-responders to caffeine ingestion may be able to derive
performance benefits from a caffeine mouth rinse. Additionally, because of the
presumed mechanisms through which caffeine consumption and mouth rinsing
elicits performance gains, one might expect there to be a further improvement in
performance when mouth rinsing in combination to ingesting caffeine than when
only ingesting caffeine.
In contrast to Beaven’s work, others have shown that a caffeine mouth rinse
given throughout a 60 minute cycling time trial does not seem to improve
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performance (12), bringing into question the efficacy of a caffeine mouth rinse for
sustained power output. Worth noting is that in a subgroup of subjects that did not
report regular caffeine consumption there was an observed ergogenic effect to the
caffeine mouth rinse even though the mouth rinse in this study contained a
relatively low concentration of caffeine that has not been shown to improve
performance during caffeine ingestion (28). Some studies have demonstrated that
“non-caffeine users” (<50mg caffeine/day) experience a heightened performance
benefit during caffeine ingestion (2) and that performance gains are attenuated in
habitual caffeine users (16).
This project was designed to address the questions outlined above.
Specifically, we aim to determine the effectiveness of a caffeinated mouth rinse on
sustained performance. As previously stated the presumed mechanisms of action of
caffeine mouth rinsing and ingestion are on the oral receptors and brain,
respectively. Differing enhancement in performance between genetic
polymorphisms, or between habituation levels of subjects will allow for the
assumption that the physiological effect of these factors occurs at either the liver or
CNS. In those that do not respond to caffeine ingestion it is possible that a caffeine
mouth rinse will elicit a performance enhancing effect that was otherwise not
observed by caffeine ingestion. If there is a separate mechanism of caffeine mouth
rinsing on the CNS then those who do not respond to caffeine ingestion potentially
could experience a performance enhancing effect of a caffeine mouth rinse.
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Aims and Hypotheses
Aim 1: To determine if a pre-exercise caffeine mouth rinse improves 3km cycling
performance compared to placebo.
Hypothesis 1: A pre-exercise caffeine mouth rinse will improve 3km cycling
performance compared to a placebo.

Aim 2: To determine if a caffeine mouth rinse influences 3km cycling performance in
C allele carriers of the CYP1A2 polymorphism.
Hypothesis 2: Genetic non-responders (C allele carriers) will not exhibit as great of a
performance improvement in response to a pre-exercise caffeine mouth
rinse when compared to placebo as genetic responders (A/A homozygous)
individuals.

Aim 3: To determine if a pre-exercise caffeine mouth rinse improves 3km cycling
performance among “caffeine-users” to a greater degree than “caffeine non
-users.”
Hypothesis 3: “Caffeine non-users” will exhibit a greater performance benefit in
response to a pre-exercise caffeine mouth rinse than “caffeine-users.”
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Aim 4: To determine if a pre-exercise caffeine mouth rinse in addition to caffeine
ingestion improves 3km cycling performance compared to caffeine ingestion
alone.
Aim 4: A pre-exercise caffeine mouth rinse in addition to caffeine ingestion will
improve 3km cycling performance more than caffeine ingestion alone.
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Significance
The current study will be the first to examine the performance enhancing
effect of a caffeinated mouth rinse on prolonged cycling, providing further evidence
of the actions of caffeine in the oral cavity. The effectiveness of caffeine ingestion in
combination with a caffeine mouth rinse at enhancing performance will be
examined to determine the potential additive effects of these two methods of
caffeine administration. Additionally, this study will yield further insight to the
factors that can effect performance improvement in regards to caffeine ingestion
including genetic responsiveness and previous caffeine intake habits. These results
may influence the use of caffeine in athletes competing in events of similar duration.

8
Chapter Two
Methods
Subjects
All subjects will be recruited from James Madison University and will be
required to have performed, at minimum, “occasional” cycling in their weekly
exercise routine. Approximately 40 recreationally trained male and female subjects
will provide written informed consent to participate in the study approved by the
James Madison University Institutional Review Board.

Testing Procedures
Cardiovascular Fitness Test - VO2max
Following height and body weight measurements, subjects will perform an
incremental exercise test on a Velotron cycle ergometer (Seattle, WA, USA) until
volitional exhaustion. Subjects will begin with a 5-minute warm-up at a selfselected pace. The subjects will then be prompted to select an intensity that “they
can maintain for 60-minutes” to begin the test. The workload will then be increased
every minute in 15 Watt (W) increments until the subject reaches volitional fatigue.
Breath samples will be collected throughout the test and oxygen consumption
(VO2max) will be measured via Moxus Modular Metabolic System (AEI Technologies,
Bastrop, TX, USA). Heart rate will be measured via Polar heart rate monitor (Lake
Success, New York, USA). A fan set on the “medium” setting will be placed 2 meters
in front of the Velotron for cooling purposes. All subjects will receive strong verbal
encouragement throughout the cardiovascular fitness test.
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Familiarization and Experimental Trials
Each subject will perform six exercise trials on a Velotron cycle ergometer,
with 3-7 days between each trial. The first two trials will serve as familiarization
trials with the subsequent four trials serving as experimental trials in a double
blind, randomized, counter-balanced, placebo controlled fashion. The subjects will
then be asked to perform a 5-minute warm-up at a self-selected intensity. Two
mouth rinses will be provided during the warm-up; one given immediately at the
onset of the warm-up, and one 30 seconds before completion of the warm-up.
Subjects will be instructed to swish the mouth rinse for 5 seconds, during which the
researcher will count down from 5. Following the warm-up subjects will perform a
3km time trial. Subjects will be instructed to treat each trial as if they are in a race.
Subjects will not receive verbal feedback or encouragement from the investigators
and no visual feedback from the time trial will be provided with the exception of
elapsed distance.

Supplementation Protocol
No supplementation will be given during the familiarization trials other than
two practice mouth rinses (water only). During the experimental trials subjects will
be given a 25ml mouth rinse solution at room temperature containing either: A)
300mg caffeine, 1g saccharine, and 25ml of water (rinse containing 1.14% caffeine)
or B) a flavor-matched placebo containing 6g saccharine, and 25ml of water.
Additionally, a 6mg/kg of body weight capsule containing either anhydrous caffeine
or all-purpose flour (placebo) will be ingested 1 hour prior to each treatment trial.
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The following are the four treatment conditions that will be administered: 1)
placebo capsule + placebo mouth rinse. 2) placebo capsule + caffeine mouth rinse 3)
caffeine capsule + caffeine mouth rinse. 4) caffeine capsule + placebo mouth rinse.

Dietary and Exercise Control
Diet
Subjects will be provided with instructions for recording food intake so that
subsequent dietary intake can be replicated. All subjects will record food intake for
24 hours prior to all experimental trials and will be asked to repeat food intake for
each treatment trial so that caloric intake is identical between trials. Subjects will be
given a copy of their previous food log so that they can easily repeat their diet for
the subsequent trial. Subjects will abstain from any alcohol, caffeine, and food, for
24, 12, and 2 hours prior to each experimental trial respectively. Dietary records
will be obtained prior to each experimental trial.

Exercise
All subjects will record daily physical activity for 48 hours prior to
experimental trials and will be asked to repeat daily physical activity for each
experimental trial. Subjects will be given a copy of their previous exercise log so that
they can easily repeat their physical activity for the subsequent trial. Subjects will be
asked to abstain from any heavy exercise 48 hours prior to each experimental trial.
Exercise records will be obtained prior to each experimental trial.
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DNA Sampling
Blood Sampling
Approximately 3 ml of blood will be obtained from an antecubital vein after
the final time trial. Blood will then be stored in a -80 degree F freezer until DNA
extraction takes place. DNA will be extracted via Illustria Blood GenomicPrep mini
spin kit (GE Healthcare, Buckinghamshire, UK). Genotyping will then be performed
using restriction fragment length polymorphism-polymerase chain reaction (RFLPPCR). Following blood genotyping, subjects will be grouped as A/A homozygous and
C allele carriers.

Treatment Blinding Efficacy
Upon conclusion of the study, subjects will be asked to identify which
treatment they received for each of the four treatment trials to confirm effectiveness
of the treatment blinding procedures.

Statistical Analysis
Univariate Analysis of Variance (ANOVA) will be applied to determine
treatment differences for all variables. Simple contrasts between treatment
conditions will be used to generate P values for subsequent analysis as described
below. Statistical analyses will be performed using IBM Statistical Package for Social
Sciences (SPSS) 21 for Macintosh (SPSS Inc., Chicago, IL, USA).
Magnitude-based inferences about the data will be derived using methods
described by Hopkins and colleagues (Hopkins et al., 2009). A previously
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established ‘smallest worthwhile change’ in performance will be used as the
threshold value for a substantial treatment effect (separate treatment conditions vs.
placebo) (Hopkins, 2004). The smallest worthwhile change in performance will be
defined as 0.3 x the within subject variability across repeated time trials (Hopkins,
2004). The coefficients of variability for the performance parameters will be derived
from the familiarization trials of the current investigation.
A published spreadsheet (Hopkins, 2007) will then be used to determine the
likelihoods of the true treatment effect (of the population) reaching the substantial
change threshold (0.3 x CV); these will be classified as <1% almost certainly no
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely,
95-99% = very likely, and >99% = almost certain. If the percent chance of the effect
reaching the substantial change threshold is <25% and the effect is clear, it will be
classified as a ‘trivial’ effect. If 90% confidence intervals included values that
exceeded the substantial change threshold for both a positive and negative effect,
effects will be classified as unclear (>5% chance of reaching the substantial
threshold for both a positive and negative effect). For ease of interpretation data
will be displayed as raw means ± SD.
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Chapter Three
Manuscript
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Abstract
PURPOSE: The objectives were to determine the effects of caffeine ingestion
and mouth rinsing on cycling performance, and to assess whether the CYP1A2 gene
is related to the size of the performance effects. METHODS: Thirty-eight recreational
cyclists completed four simulated 3-kilometer time trials (TT). Subjects ingested
either 6mg/kgBW of caffeine or placebo one hour prior to each TT. Additionally, 25
ml of 1.14% caffeine, or placebo solution was mouth rinsed before each TT.
Treatments were: placebo ingestion+placebo rinse (Placebo), placebo
ingestion+caffeine rinse (Rinse), caffeine ingestion+caffeine rinse (Ingestion+Rinse),
caffeine ingestion+placebo rinse (Ingestion). Subjects were genotyped and classified
as AA homozygotes or C allele carriers for the rs762551 polymorphism in CYP1A2.
Magnitude based inferences were used to evaluate treatment differences. RESULTS:
Both Ingestion+Rinse (‘likely’) and Ingestion (‘possibly’) improved performance
compared to Placebo. Performance differences between Ingestion+Rinse and
Ingestion and between Rinse and Placebo were ‘likely trivial.’ C allele carriers
experienced greater gains (‘likely’) with Ingestion compared to AA homozygotes.
Additional analyses revealed that caffeine intake conferred larger benefits for
subjects that performed trials prior to 10am. CONCLUSIONS: Caffeine ingestion, but
not mouth rinse, improved cycling performance. C allele carriers experienced the
largest improvement in performance with caffeine ingestion, especially prior to
10am.

Keywords: CYP1A2, genetics, circadian rhythm, mouthwash
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Introduction
Caffeine intake can improve high intensity performance across a continuum
of activities, including swimming (Collomp et al., 1992), rowing (Bruce et al., 2000),
running (Wiles et al., 1992; Glaister et al., 2008), cycling (Wiles et al., 2006; Santos et
al., 2013), and variable intensity activities (Schneiker et al., 2006; Klein et al., 2012).
Though unsettled, caffeine is believed to deliver its performance enhancing effects
through the central nervous system by blocking adenosine receptors (Ribeiro &
Sebastião, 2010) and increasing neural excitability (Walton et al., 2003). This can
enhance motor output (Black et al., 2014) and suppress ratings of perceived
exertion and pain (Doherty et al., 2005; Motl et al., 2003).
Considerable individual variability associated with the performance benefits
of caffeine has long been recognized (Doherty et al., 2002; Meyers & Cafarelli, 2005;
Robertson et al., 1978). Genetics have been offered as a possible explanation and
viable gene candidates have been identified. For instance, there are genetic
variations of the primary enzyme responsible for caffeine metabolism – CYP1A2
(Yang et al., 2010). Homozygosity for the A allele at intron 1 of the CYP1A2 gene
increases the inducibility of the enzyme (Sachse et al., 2009). This presumably
influences the rate of caffeine metabolism and resultant concentrations of caffeine
and caffeine metabolites in the blood. Based on this concept our laboratory recently
investigated whether CYP1A2 genotype impacts the performance benefits of
caffeine. We reported that individuals homozygous for the A allele experienced a
larger ergogenic effect (Womack et al., 2012). This may partially explain the variable
performance benefits of caffeine intake.
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Interestingly, some investigators have recently observed that rinsing caffeine
in the mouth, without ingestion, enhances repeated sprint (Beaven et al., 2013) and
30-minute (Bottoms et al., 2014) cycling performance. It is possible that
unidentified receptors in the oral cavity provide afferent feedback in a manner that
enhances physical performance, much like what has been shown with carbohydrate
rinsing (Chambers et al., 2009). However, recent data refuting the benefits of a
caffeine rinse for 60-min cycling performance (Doering et al., 2013) calls this into
question and necessitates more work in this area. If mouth rinsing with caffeine
ultimately proves beneficial, it could be a practical strategy to avoid the genetic
disadvantages associated with alterations in caffeine metabolism, as the ergogenic
effect of mouth rinsing would not be affected by hepatic clearance.
Therefore, this study was designed to assess the efficacy of caffeine mouth
rinsing on 3-km cycling time trial performance and to determine if caffeine mouth
rinsing affects the magnitude of performance gains influenced by the CYP1A2
polymorphism. Because subjects self-selected the time of day at which they
performed their laboratory trials, we also had the opportunity to preliminarily
examine the possibility that time of day alters the effects of caffeine on cycling
performance
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Materials and Methods
Subjects
Thirty-eight recreationally trained male and female subjects from James
Madison University participated in this study (demographics reported in Table 2).
Subjects were required to have performed, at minimum, “occasional” cycling (one
day per week) in their typical weekly exercise routine. Subjects were informed of
the experimental procedures and risks prior to giving written consent. The study
was approved by the James Madison University Institutional Review Board.

Cardiorespiratory Fitness
Following height and body weight measurements, subjects performed an
incremental exercise test to exhaustion on a bicycle ergometer (Velotron,
Racermate, Inc., Seattle, WA, USA) to determine VO2max. Subjects began with a 5minute warm-up at a self-selected intensity. Subjects then were prompted to select
an intensity that could be maintained for 60-minutes to begin the test. Workload
was increased in 15 W increments every minute until volitional fatigue. Metabolic
measurements were assessed via Moxus Modular Metabolic System (AEI
Technologies, Pittsburgh, PA, USA) throughout the test and VO2max was determined
by the highest 30 s mean oxygen uptake value. A fan set on the medium setting was
placed 2 meters in front of the ergometer to cool subjects.
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Supplementation
A randomly counterbalanced, double blind, placebo controlled design was
implemented to compare the effects of the four treatment conditions. During the
experimental trials subjects were given two 25ml mouth rinse solutions at room
temperature containing either: A) 300mg caffeine (NutraBio Labs, Inc., Middlesex,
NJ), 1g saccharine (Sweet’N Low, Brooklyn, NY), and 25ml of water (rinse containing
1.14% caffeine) or B) a flavor-matched placebo containing 6g saccharine, and 25ml
of water. Additionally, a 6mg/kg body weight capsule containing either anhydrous
caffeine or all-purpose flour (placebo) was ingested 1 hour prior to each treatment
trial. The four treatments consisted of a 2 x 2 factorial of capsule and mouth rinse
treatments: 1. placebo capsule + placebo mouth rinse (Placebo) 2. placebo capsule +
caffeine mouth rinse (Rinse) 3. caffeine capsule + caffeine mouth rinse
(Ingestion+Rinse) 4. caffeine capsule + placebo mouth rinse (Ingestion).

Performance Trials
Each subject performed six exercise trials (two familiarization trials followed
by four experimental trials) on the aforementioned cycle ergometer, with 3-7 days
between each trial. Trials were performed at the same time of day to eliminate any
possible within-subject circadian effects on performance. The subjects performed a
5-minute warm-up at a self-selected intensity. Two mouth rinses were provided
during the warm-up; one immediately at the onset of the warm-up, and another 30
seconds before completion of the warm-up. Subjects swirled the mouth rinse for five
seconds and then expectorated the rinse. Following the warm-up subjects

20
performed a 3km time trial. Familiarization trials were identical to the experimental
trials, with the exception that subjects rinsed with water. Subjects were instructed
to treat each trial as a competition. Subjects did not receive verbal feedback or
encouragement from the investigators and no visual feedback from the time trial
were provided, with the exception of elapsed distance.
Average power output during the first, second, and third kilometers were
also analyzed to determine if any pacing differences were present between
treatments.

Time of Day
Subjects were divided into two separate groups based on the time of day that
they performed laboratory trials. 10:00am was selected as the threshold as it
emerged as a natural breakpoint and created a group of 15 subjects that performed
Early trials and 23 subjects that performed Late trials. To evaluate the effect of
caffeine ingestion on change in performance the Ingestion and Ingestion+Rinse
treatments were averaged for each subject and then compared to placebo.

Dietary and Exercise Control
Subjects recorded food intake for 24 hours prior to the initial experimental
trial and were instructed to replicate food intake for the 24-hour period prior to
each experimental trial. Subjects were instructed to abstain from any alcohol (24
hrs), caffeine (12 hrs), and food intake (2 hrs) prior to each experimental trial. All
subjects recorded daily physical activity for 48 hours prior to experimental trials.
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Subjects were instructed to maintain consistent exercise habits between trials and
to abstain from any heavy and/or unaccustomed exercise 48 hours prior to each
experimental trial.

DNA Sampling
Blood samples [~3ml sample – 5ml BD Vacutainer tube (Becton Dickinson &
Company, Franklin Lakes, NJ, USA)] were obtained from an antecubital vein after the
final time trial. Blood was then stored at -80 oC until DNA extraction. DNA was
extracted via Illustria Blood GenomicPrep mini spin kit (GE Healthcare,
Buckinghamshire, UK). Genotyping was then performed using restriction fragment
length polymorphism-polymerase chain reaction (RFLP-PCR). Following
genotyping, subjects were grouped as AA homozygous (i.e. ‘fast’ metabolizers) and C
allele carriers (i.e. ‘slow’ metabolizers) of the rs762551 single nucleotide
polymorphism in the CYP1A2 gene.

Statistical Analysis
Univariate Analysis of Variance (ANOVA) was applied to determine
treatment differences. Simple contrasts between treatment conditions were used to
generate P values for analyses described below. Independent t-tests were used for
between group comparisons of genotype, and time of day. All data were log
transformed to diminish the effects of nonuniformity. Statistical analyses were
performed using IBM Statistical Package for Social Sciences (SPSS) 21 for Macintosh
(SPSS Inc., Chicago, IL, USA).
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Magnitude-based inferences about the data were derived using methods
described by Hopkins and colleagues (Hopkins et al., 2009). A previously
established ‘smallest worthwhile change’ in performance was used as the threshold
value for a substantial treatment effect (separate treatment conditions vs. placebo)
(Hopkins, 2004). The smallest worthwhile change in performance was defined as
0.3 x the within subject variability (CV=2.3%; calculated from familiarization trials)
across repeated time trials, which translated to a 2.1 s difference in performance
(Hopkins, 2004).
A published spreadsheet (Hopkins, 2007) was then used to determine the
likelihood of the true treatment effect (of the population) reaching the substantial
change threshold (0.3 x CV); these were classified as <1% almost certainly no
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely,
95-99% = very likely, and >99% = almost certain. If the percent chance of the effect
reaching the substantial change threshold was <25% and the effect was clear, it was
classified as a ‘trivial’ effect. If 90% confidence intervals included values that
exceeded the substantial change threshold for both a positive and negative effect,
effects were classified as unclear (>5% chance of reaching the substantial threshold
for both a positive and negative effect). For ease of interpretation data is displayed
as raw means ± SD.
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Results
Performance
Ingestion+Rinse ‘likely’ improved performance by 1.4% ± 3.3% when
compared with Placebo, whereas Ingestion ‘possibly’ enhanced performance by
1.1% ± 4.1%. Rinse had a ‘likely trivial’ effect on time trial performance.
Performance differences between Ingestion+Rinse and Ingestion and between Rinse
and Placebo were ‘likely trivial’. Mean performance times are displayed in Table 1
and mean difference of treatment effects (treatment times – placebo times) with 90
percent confidence intervals are displayed in Figure 1.

Genetics
Twenty-one (55%) subjects were homozygous for the A allele and seventeen
(45%) were C allele carriers. Descriptive characteristics of the two genotype groups
are shown in Table 2. Among C allele carriers, performance was ‘likely’ improved by
2.0% ± 4.0% and by 1.8% ± 3.4% with both Ingestion and Ingestion+Rinse
respectively, whereas AA homozygotes ‘possibly’ benefited by 1.0% ± 3.2% with
Ingestion+Rinse. All other treatment effects were ‘unclear’. Note that there ‘likely’
was a difference in performance improvement with Ingestion between the AA and
AC genotypes. Mean treatment effects are displayed in Figure 2.

Time of Day
Fifteen (39%) subjects performed trials prior to 10am (Early), of whom
seven were C allele carriers and eight were AA homozygotes. Twenty-three (61%)
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subjects performed trials later than 10am (Late), of whom ten were C allele carriers
and thirteen were AA homozygotes. Performance was ‘almost certainly’ improved
with caffeine ingestion in Early subjects by 2.0 ± 2.5%, and ‘possibly’ improved in
Late subjects by 0.7 ± 4.3%. Among C allele carriers, caffeine ingestion ‘almost
certainly’ and ‘possibly’ improved performance by 3.5 ± 2.1% and 0.6 ± 2.1% in
Early and Late subjects respectively. Mean treatment effects are displayed in Figure
3.
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Discussion
The primary goal of this project was to determine if caffeine mouth rinsing
and ingestion, alone and in combination, benefit 3km cycling performance, and if
effects occurred regardless of CYP1A2 genotype. Although caffeine ingestion
improved performance compared to placebo, mouth rinsing had only a trivial effect,
regardless of genotype. Also, in contrast to a recent investigation from our
laboratory (Womack et al., 2014), C allele carriers experienced greater performance
gains with caffeine ingestion than AA homozygotes. More data need to be gathered
to provide a sound explanation for this observation. Finally, the post-hoc time of day
analyses revealed that caffeine imparted marked benefits when trials were
performed Early compared to Late. To our knowledge, this is the first evidence that
time of day may impact the magnitude of the effect that caffeine has on cycling
performance.
The current data conflict with previous reports that caffeine mouth rinsing
can augment 30-minute cycling performance (Bottoms et al., 2014) and power
output during repeated sprints (Beaven at al., 2013). However, in line with the
current results, Doering’s work indicates that caffeine rinsing does not affect ~60min cycling performance (Doering et al., 2013). We were not able to identify
experimental commonalities or differences that would explain why these protocols
yielded different results. So, when our data are combined with Doering, and
considered with the fact that there are no known oropharangeal receptors for
caffeine, we question the utility of caffeine rinsing for performance. However, there
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is enough support (Bottoms et al., 2014; Beaven et al. 2013) to warrant follow-up
work before unequivocal conclusions are made.
Despite the failure of a caffeine mouth rinse to improve TT performance,
caffeine ingestion did enhance performance, as has been demonstrated previously
during cycling performances of similar duration (Wiles et al., 2006; Santos et al.,
2013). The observation that caffeine intake improved performance supports the
efficacy of the current study design and strengthens the interpretation of the mouth
rinse findings. In light of the overall mouth rinse results, caffeine mouth rinsing did
not benefit the genetic ‘non-responders’, nor did it further benefit performance
when provided along with caffeine ingestion.
We recently reported that AA homozygotes exhibited larger performance
benefits with caffeine ingestion, compared to their C allele counterparts (Womack et
al. 2014). Thus we expected that the AA homozygotes again would experience a
more marked performance enhancement. Surprisingly, the C allele carriers
experienced greater gains in performance with caffeine ingestion than did the AA
homozygotes. Because of the size and individual consistency of the effect across
projects, we do not believe that either finding is coincidental. Yet, there is no clear
explanation for the opposing results. One difference between studies is training
status. The previous sample population consisted of competitive cyclists, whereas
subjects in the current study were recreational cyclists who reported cycling only
~2 days per week. CYP1A2 expression is induced following acute exercise
(Kochanska-Dziurowicz et al., 2014) and exercise training (Vistisen et al., 1992).
Additionally, some have shown that adenosine receptor (the target of caffeine and
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caffeine metabolites) density in skeletal and cardiac muscle is greater in endurancetrained than untrained men (Mizuno et al. 2005). Therefore, it may be that training
history and/or current fitness level influences the substrate-receptor interaction
between caffeine/metabolites and adenosine receptors, thereby altering the
genotype x caffeine effect. Prospective studies should consider evaluating
differences in caffeine metabolites across genotype and training status.
Though not a priori, the time of day analysis revealed that the benefits of
caffeine may be exaggerated Early (<10:00am) in the day. Caffeine ingestion
improved performance to a greater extent in the Early trials compared to the Late
trials. This is in line with recent findings that caffeine ingestion has a larger effect on
neuromuscular performance in the morning than in the afternoon. It seems that the
improvement in performance seen in the morning simply elevates performance to
what is seen in the afternoon during placebo conditions, with only minimal
improvement due to caffeine ingestion in the afternoon (Mora-Rodriguez et al.,
2012; Mora-Rodriguez et al., 2014). Additionally, we found that the C allele carriers
seemed to be driving the effect in the Early trials. All seven C allele carriers who
performed Early trials performed better with caffeine ingestion, whereas this was
true in only five of the eight Early AA carriers. Interestingly, CYP1A2 activity is
elevated in the morning compared to the evening (Perera et al., 2013), which may
contribute to the ergogenic effect of caffeine; consequently adding yet another
variable to consider when interpreting the physiological effects of caffeine intake.
It is important to note that all but one of the Early subjects were fasted (over
night) whereas twenty of the twenty-three Late subjects had eaten during the days
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of their performance trials, raising the possibility that feeding status factored into
the time of day results. However, improvements in performance due to caffeine
ingestion have been demonstrated following 6-12 hour fasting (MacIntosh & Wright,
1995; Bruce et al., 2000), and when feedings have taken place approximately 2
hours before testing (Collomp et al., 1992; Schneiker et al., 2006). Moreover, the
previously mentioned time-of-day study by Mora-Rodriguez et al. gave subjects a
624kcal bolus one hour prior to all testing, suggesting that fasting does not play a
role in the ergogenic effect of caffeine (2014). To our knowledge no studies have
directly examined the effect of feeding status on performance following caffeine
ingestion. Future investigations should determine whether the time of day and/or
fasting influence the performance response to caffeine ingestion.
The present study demonstrates that caffeine mouth rinsing does not affect
3km cycling performance in recreational cyclists. As expected there was an
improvement in 3km performance with caffeine ingestion, but there was no further
improvement with caffeine ingestion and mouth rinse in combination. Surprisingly,
there was a greater performance enhancement in C allele carriers compared to AA
homozygotes following caffeine ingestion, thus necessitating follow-up work to
explain the dissimilar results compared to our previous work. Finally a greater
performance enhancement with caffeine ingestion was observed in Early trials
compared to Late trials.
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Perspectives
The present study provides additional evidence of genetic (genotype) and
circadian (time of day) factors that affect the ergogenic value of caffeine intake and
may allow for prescription of more personalized caffeine intake strategies to
maximize performance. For example, perhaps genetics contribute to caffeine
metabolism in a manner that would affect the optimal timing and dosage for a
particular subject. Further, the time at which caffeine is consumed may strongly
influence the magnitude of the desired effect. Future research is critical for the
development of personalized caffeine intake guidelines for athletes.
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Figure Legends
Figure 1
Effects of Caffeine Mouth Rinsing and Ingestion on 3km Time Trial Performance:
Circles indicate mean treatment differences from placebo and bars depict a ± 90%
confidence interval of Rinse, Ingestion, and Ingestion+Rinse vs. Placebo. Dashed lines
signify threshold value for a meaningful effect (0.3 x CV). * Signifies a ‘likely’
improvement in performance. † Signifies a ‘possible’ improvement in performance.
Placebo = placebo ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse,
Ingestion+Rinse = caffeine ingestion+caffeine rinse, Ingestion = caffeine
ingestion+placebo rinse.

Figure 2
Effect of Genotype on the Treatment Effect of Caffeine Mouth Rinse and Ingestion
During 3km Time Trial Performance: Bars indicate mean treatment differences from
placebo and bars depict a ± 90% confidence interval of Rinse, Ingestion, and
Ingestion+Rinse vs. Placebo. * Signifies a ‘likely’ improvement in performance. †
Signifies a ‘possible’ improvement in performance. ‡ Signifies a ‘likely’ difference in
performance improvement between the AA and AC Genotypes. Placebo = placebo
ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse, Ingestion+Rinse =
caffeine ingestion+caffeine rinse, Ingestion = caffeine ingestion+placebo rinse.
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Figure 3
Influence of Time of Day on the Treatment Effect of Caffeine Ingestion During 3km
Time Trial Performance: Bars depict the treatment effects (± 90% CI) of Overall, C
allele carrier, and AA homozygote performance with caffeine ingestion. * Signifies an
‘almost certain’ improvement in performance. † Signifies a ‘possible’ improvement
in performance.
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Table 1. 3-km Time Trial Performance
Placebo
Mean Time ± SD (seconds) 313.7 ± 30.9

Rinse
314.1 ± 29.1

Ingestion
310.2 ± 30.9†

Ing+Rinse
309.0 ± 27.4*

† Signifies a ‘possible’ improvement in performance compared to Placebo. * Signifies a ‘likely’ improvement in performance
compared to Placebo. Placebo = placebo ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse, Ingestion+Rinse =
caffeine ingestion+caffeine rinse, Ingestion = caffeine ingestion+placebo rinse.
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Table 2. Descriptive data of subjects for AA homozygotes
All Subjects (n = 38)
Height (cm)
171.0 ± 13.7
Weight (kg)
70.9 ± 11.9
Age (years)
21.6 ± 1.5
VO2 max (ml/kg/min)
51.4 ± 6.8

and C allele carriers
AA (n = 21)
167.2 ± 16.9
68.0 ± 13.8
20.8 ± 1.4
51.1 ± 7.0

C (n = 17)
175.7 ± 6.2
74.5 ± 8.0
21.6 ± 1.5
51.9 ± 6.2
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Figure 2. Genotype and Time Trial Performance
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Figure 3. Time-of-Day and Time Trial Performance
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Appendix I

James Madison University
Department of Kinesiology
Consent for Investigative Procedure
I, ______________________, hereby agree on _____________ (date) to participate in the
research project conducted by Christopher J. Womack, Ph.D., Nicholas D. Luden,
Ph.D., Mike Saunders, Ph.D., Mark Pataky, and Jenna Goffe from James Madison
University titled The Influence of a CYP1A2 Polymorphism on the Ergogenic Effects of
a Caffeine Mouth rinse.
The purpose of this study is to determine whether or not mouth rinsing with
caffeine enhances high intensity cycling performance in individuals that do not
benefit from caffeine intake due to their genetic predisposition.
Subject Responsibility
I understand that I will undergo the following testing in the study:
This study consists of seven separate exercise tests performed on a stationary cycle
(cardiovascular fitness test, two familiarization tests, and 4 3-km time trial tests). All
testing will occur in Godwin Hall, room 209, on the campus of James Madison
University. You will also be asked about lifestyle behavior such as smoking and
physical activity and complete dietary and physical activity records. The total time
commitment is estimated to be less than four hours.
Cardiovascular Fitness Test:
If you meet the criteria for the study, the researchers will measure your height and
body weight and you will then be asked to perform a cardiovascular fitness test on a
bicycle ergometer to determine your peak oxygen consumption (VO2max). You will be
asked to ride stationary bicycle ergometer at an initial workload that is ‘fairly easy’.
The workload will be increased every two minutes during the test. You will be
encouraged to continue to cycle until you request to stop due to fatigue or are
unable to continue at a cadence of >50 revolutions per minute. To assess oxygen
consumption throughout the test, you
will need to breathe through a
mouthpiece/breathing apparatus that collects your expired breath throughout the
test (10-15 minutes).
Familiarization and Time Trial Sessions:
During the familiarization and time trials, you will be asked to complete a 5-min
warm up at a self selected intensity followed by 3-km time trial (TT) on a cycle
ergometer that will last 3-5 minutes. Each time trial is to be approached with a
competition mentality. Between test preparation and completion of the exercise
test, each of these tests should take approximately 15-20 minutes.
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Supplementation Protocol:
No supplementation will be provided during the familiarization trials. However, you
will be asked to practice with the mouth rinse prior to these trials. For the mouth
rinse, Dixie cups filled with 25 ml of solution with or without caffeine will be
provided 5 minutes, and 30 seconds prior to the TT. You will be instructed to swish
the solution in your mouth for 10 seconds, upon which you will spit it into a bucket.
The remaining four visits will be experimental trials whereby separate treatments
will be provided. The treatments will be: 1. Caffeine mouth rinse; mouth rinse
solution administered immediately prior to- and during exercise where you will be
instructed to only rinse the caffeine solution in your mouth and then spit it out
(without swallowing). A placebo pill will also be administered 1 hour prior to the
trial. 2. Caffeine pill; you will ingest the pill whole 1 hour prior to the TT. A placebo
mouth rinse solution will also be administered. 3. Caffeine pill + caffeine mouth
rinse; a caffeine pill and caffeine mouth rinse will be administered. 4. Placebo; a
placebo pill and placebo mouth rinse will be administered.
Dietary, Exercise, and Time of Day Controls:
You will record food intake 24 hours prior to your first experimental trial. You will
then be provided with a copy of your initial dietary log, which you will be asked to
use to replicate your food intake for 24 hrs preceding each subsequent experimental
trial. Additionally, you will abstain from any alcohol and caffeine for 24 hrs and 12
hrs prior to the experimental trials, respectively. Finally, you will avoid food intake
for 2 hours preceding each experimental trial.
You will avoid heavy exercise for 48 hrs prior to each experimental trial, record all
physical activity performed during this time frame, and maintain consistent exercise
habits between trials
All experimental trials will be separated by 3-7 days and performed at the same
time of day, with all trials starting within a 2-hour range.

DNA Sampling:
We will extract a sample of your DNA from your blood sample. The DNA will be
stored in our laboratory freezer for up to 3 years, but the sample will be coded so
that nobody except the primary investigators can detect which sample is yours. The
DNA testing will involve determining sequences of DNA for specific genes that are
related to caffeine metabolism. We will not use this DNA for any other purpose. The
results of this genetic testing will only be available to the primary investigator and
you. These results will not be made public and will be stored in a locked file cabinet.
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Potential Risks
According to the American College of Sports Medicine’s Guidelines for Exercise
Testing and Prescription, the risk associated with vigorous exercise in individuals
categorized as “low risk” is very minimal, and physician supervision is not
necessary. The exercise testing conditions are likely safer than the typical exercise
environments of the participants. Subjects that do not meet ACSM criteria for “low
risk” will not be allowed to participate in the study. A physician will be available by
pager if the need for medical attention arises throughout the study period. In the
unlikely event of cardiac or other complications during exercise, an emergency plan
is in place. This includes immediate access to a phone to call emergency personnel.
In addition, at least one of the listed investigators will be present during all
laboratory testing sessions, and all are CPR certified.
The risks of blood sampling using venipuncture include possible mild bruising, and
the risk of transfer of blood-borne pathogens, as well as possible risks of infection or
skin irritation. These risks are considered to be minimal, and all safety precautions
for handing blood samples will be followed according to Occupational Safety and
Health Administration (OSHA) protocols, including: investigators will wear latex
gloves at all times during blood sampling and testing. A sharps container lined with
a biohazard bag will be used for all sharp objects involved in the blood sampling; all
other materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in
a separate waste disposal unit lined with a biohazard bag. All trash bags will be
taken to Rockingham Memorial Hospital for disposal. All investigators who will be
involved in blood draws (and handling of blood) have been trained in these
phlebotomy techniques, and completed JMU blood-borne pathogen training.
If you have a wheat allergy you should not participate in this study.
Potential Benefits
There are no known direct benefits. However, volunteering for this project will help
determine the impact of a caffeine mouth rinse on cycling performance. Performance
Incentive – This monetary benefit will only apply to two males and two females. The
top 5 female performers (fastest finishing time under the placebo conditions) will be
entered into a drawing to win a single $150 WellsOne Prepaid Visa Card whereas
performers 6-10 will be entered into a drawing to win a single $75 Card. An
identical approach will be applied to male subjects (1 $150 Card and 1 $75 Card).
Confidentiality
The results of this research will be presented at conferences and published in
exercise science journals. The results of this project will be coded in such a way that
your identity will not be attached to the final form of this study. The researcher
retains the right to use and publish non-identifiable data. However, you can ask that
your data be removed from the study at any point prior to presentation and
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publication. While individual responses are confidential, aggregate data will be
presented representing averages or generalizations about the responses as a whole.
All data will be stored in a secure location accessible only to the researcher. Final
aggregate results will be made available to you upon request.

Participation & Withdrawal
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without
consequences of any kind. Your right to withdraw includes the right to request that
your DNA and blood samples be discarded at any time. You should be aware that
the DNA sample is subject to court subpoena.
Questions
You may have questions or concerns during the time of your participation in this
study, or after its completion. If you have any questions about the study, contact
Nicholas D. Luden, Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068.
Giving of Consent
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given
satisfactory answers to my questions. The investigator provided me with a copy of
this form. I certify that I am at least 18 years of age.

Name of Participant (Printed)

Name of Researcher(s) (Printed)

Name of Participant (Signed)

Name of Researcher(s) (Signed)

Date

Date

For questions about your rights as a research subject, you may contact the chair of
JMU’s Institutional Review Board (IRB). Dr. David Cockley, (540) 568-2834,
cocklede@jmu.edu.
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James Madison University
Department of Kinesiology
Health Status Questionnaire

Instructions: Complete each question accurately. All information provided is
confidential.
Part I: General Information
1. Sex: Male

Female

2. Participant Number:
3. Date of Birth (Month/ Day/ Year)

Part II: Medical History
4. Circle any that died of heart attack before age 65: Father Mother Brother
Sister Grandparent
5. Date of last medical exam: _____________ Last physical fitness test:
_______________
6. Circle operations you have had: Back Heart Kidney Eyes
Ears Hernia
Lung

Joint

Neck

Other ________________

7. Please circle any of the following for which you have been diagnosed or
treated by a physician or health professional:
Alcoholism
Diabetes
Anemia (sickle cell) Emphysema
Anemia (other)
Epilepsy
Asthma
Eye Problems
Back Strain
Gout
Bleeding trait
Hearing Loss
Bronchitis, chronic Heart Problem
Cancer
High Blood Pressure
Cirrhosis, liver
Hypoglycemia
Concussion
Hyperglycemia
Congenital defect
Infectious Mononucleosis
Other _____________________

Kidney Problems
Mental Illness
Muscular Injury
Neck Strain
Obesity
Orthopedic Injuries
Phlebitis
Rheumatoid arthritis
Stroke
Thyroid problem
Ulcer
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8. Circle all medications taken in the last six months:
Blood thinner Epilepsy medication
Diabetic pill
Heart-rhythm medication
__________________
Digitalis
High-blood pressure medication
Diuretic
Insulin

Nitroglycerin
Other

9. Any of these health symptoms that occur frequently is the basis for medical
attention. Circle the number indicating how often you have each of the following:
5 = Very often 4 = Fairly often 3 = Sometimes 2 = Infrequently 1=
Practically never
a. cough up blood
1 2 3 4 5

f. chest pain
1 2 3 4 5

b. abdominal pain
1 2 3 4 5

g. swollen joints
1 2 3 4 5

c. low back pain
1 2 3 4 5

h. feel faint
1 2 3 4 5

d. leg pain
1 2 3 4 5

i. dizziness
1 2 3 4 5

e. arm or shoulder pain
1 2 3 4 5

j. breathless on slight exertion
1 2 3 4 5

Part III: Health Related Behavior
10. Do you smoke? Yes

No

11. If you are a smoker, indicate the number of smoked per day:
Cigarettes:
40 or more

20-39

10-19

1-9

Cigars or pipes only:
5 or more or any inhaled less than 5, none inhaled
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12. Do you exercise regularly? Yes No

13. How many times in a week do you spend at least 30 minutes in moderate to
strenuous/vigorous exercise?
1

2

3

4

5

6

7

days per week

Average Exercise Habits over the Past 2 Months:
Avg. # days of exercise per week
Avg. # of days of aerobic exercise per week
Avg. # of days of cycling per week

14. Can you walk 4 miles briskly without fatigue? Yes No
15. Can you jog 3 miles continuously at a moderate pace without discomfort?
Yes
No
16. Weight now: __________ lb. One year ago: __________ lb Age 21:
__________ lb

Appendix III
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Caffeine Habits Questionnaire

Please list your approximate WEEKLY intake of the following
Cups of coffee:
Cups of tea:
Cans (12oz) of caffeinated soda:
Servings of chocolate:
Doses of caffeinated pills (No-Doz, Vivarin, etc.):
Other caffeinated beverages not listed (please list specific drink and weekly intake):

Appendix IV
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INSTRUCTIONS FOR KEEPING YOUR 24-HOUR FOOD RECORD
Keep your record for three days per trial. You will include the day before, the day of,
and the day after each trial. Include all meals, snacks, nibbling, and beverages
including water and cocktails
1. Fill out the date and day of the week at the top of food record sheet
2. Record the time you consumed your food and/or drink. To be most accurate,
fill out the food record as soon as you finish eating.
3. List the first food and/or drink you consumed when you began your day and
continue to record until you consume your last food and/or drink of your day
(usually before bedtime)
4. List each food and/or drink on a separate line
Example: cereal with milk, cereal and milk should each be on separate lines
spaghetti, noodles and sauce should each be on separate lines
Combination foods:
List parts of food on separate lines
Include preparation method, quantity, and brand name of each food
Example: Sandwich (4 oz healthy choice turkey, 2 slices Sara Lee
wheat bread, 1 tbsp Hellman’s light mayo, 2 oz Kraft American
cheese, 1 slice of red fresh tomato)
5. Record the method of preparation
Example: fried, baked, grilled
salt, oil (olive, canola, corn, other) butter or margarine, spices, etc.
6. Record quantity consumed
Do not record any food not eaten
Example: two cups of vegetables but ate half, so record one cup
Quantity of food and/or drink
Example: cups, ounces, liters, grams, each, or other unit of measure
Example: 1 cup of vegetables, 4 ounces of meat, one medium apple
7. Record brand name
Example: fast food chain name and/or package name
Example: Wendy’s, Betty Crocker, Lean Cuisine, Gatorade
8. Place any helpful food labels in manila envelope that is attached to folder
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USE THE FOLLOWING TO HELP DETERMINE PORTION SIZES AND TYPES OF FOODS
PLEASE SPECIFY
Sugar or creamer?
Beverages

Breads

Regular or sugar-free?
Alcohol content?
Name of drink and ingredients (if mixed drink)
Butter or margarine added?
Milk, sugar, or fruit added?

Cereal/Milk

The type of milk? (skim, 1%, 2%, whole)
Cereal: dry or cooked measure?
Is yogurt fruited or plain?

Dairy

% fat of milk or yogurt?
Indicate brand name of cheese substitute and/or

nondairy creamer.

Whipped topping added?
Frosting?
Desserts

Fat modified (i.e., reduced)?
Sugar-free?
Preparation method (scrambled, hard-boiled, etc)?

Eggs

Fat used in cooking?
What restaurant?
If not a national fast food chain, describe food in detail

Fast Food

Size order of fries? Super-size?
ExtRa toppings on sandwich?
Regular or salt-free?
Stick, tub, or liquid margarine?

Fats/Oils
Reduced calorie or diet product?
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Water or oil packed (fresh or canned)?
Baked or fried (With batter or without)?
Fish

Type of fat added?
Raw or cooked weight?
Sweetened or unsweetened?

Fruit

Fresh, canned, or frozen?
With or without skin?
Visible fat removed?

Meats

Light or dark meat? Raw or cooked?
Regular or reduced-calorie?

Sugars and Sweets
Don’t forget hard candy as well as chocolate.
Raw or cooked?
Fresh, frozen, or canned?
Vegetables

Low-sodium or regular?
Added fat or sauce?
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Helpful Hints with Portion Sizes
•
•

•

•

•

•

•

1 teaspoon (5 ml)
o about the size of the top half / tip of your thumb
1oz (28g)
o approximately inch cube of cheese
o volume of four stacked dice
o slice of cheese is about the size of a 3 1/2 inch computer disk
o chunk of cheese is about as thick as 2 dominoes
o 1 handful (palm) of nuts
2 ounces (57 g)
o 1 small chicken leg or thigh
o 1/2 cup of cottage cheese or tuna
3 ounces (85 g)
o serving of meat is about the size of a deck of playing cards (3 exchanges)
o the size of the palm of your hand
o 1/2 of whole chicken breast
o 1 medium pork chop
o 1 small hamburger
o unbreaded fish fillet
1/2 cup (118 ml)
o fruit or vegetables can fit in the palm of your hand
o about the volume of a tennis ball
1 cup (236 ml)
o about the size of a woman's fist
o breakfast cereal goes halfway up the side of a standard cereal bowl
o broccoli is about the size of a light bulb
1 medium apple = A tennis ball
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Appendix V
24-HOUR DIET RECORD
Subject number____________

Time

Date______________

Food and/or Drink

Day of Week______________

Method of Preparation

Quantity Consumed

Adapted From: Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of America: Mosby; 1996

Brand Name

Appendix VI

Daily Activity Records
Subject #
Date

Trial #
Type of Exercise Performed

Intensity Scale
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Very, very light
Very light
Fairly light
Somewhat hard
Hard
Very hard
Very, very hard

Date:
Duration of Exercise
(minutes)

Intensity of Exercise
(use scale below)
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Treatment Recall
Subject Number: ______________
Date: _______________

Trial 1
CAF

Trial 2

PLA

Confidence:

___________

___________

___________

___________

Trial 1

Trial 2

Trial 3

Trial 4

PLA

CAF

Confidence:

___________

PLA

CAF

CAF

___________

PLA

PLA

CAF

Trial 4

Capsule:

Rinse:

PLA

Trial 3

CAF

___________

PLA

PLA

CAF

CAF

___________

**Confidence rated on a scale from 1-10. 10 being 100% confident and 1 being not
confident at all.
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